Titin剪接调控calpain 3基因治疗肢带型肌营养不良2A型相关心脏毒性
在calpain 3与dysferlin双敲除严重小鼠模型中进行初步剂量研究,并评估AAV9-desmin-hCAPN3载体以3×10^13病毒基因组/kg剂量给予非人灵长类(NHP)的安全性与生物分布;载体给药未导致NHP可观察的不良反应或可检测毒性,心脏形态或功能无异常改变,同时在骨骼肌达到治疗性表达;对小鼠基因转移后心脏毒性及titin作用的进一步研究提示物种特异性titin剪接。
要点
- AAV9-desmin-hCAPN3以3×10^13病毒基因组/kg给予NHP,未观察到不良反应或可检测毒性。
- 转基因表达未使注射动物心脏形态或功能产生异常改变,并在骨骼肌达到治疗性表达。
- 小鼠与NHP及人类相比缓冲calpain 3活性的能力降低,可能与物种特异性titin剪接有关。
核心结论
- 系统性calpain 3载体递送在NHP中显示出有效且安全的特征,为calpain 3基因治疗在人类中的临床潜力提供关键支持。
研究设计与样本
- 在calpain 3与dysferlin双敲除严重小鼠模型中进行初步剂量研究。
- 评估AAV9-desmin-hCAPN3载体以3×10^13病毒基因组/kg剂量给予非人灵长类(NHP)的安全性与生物分布。
主要发现
- 载体给药未导致NHP可观察的不良反应或可检测毒性。
- 转基因表达未使注射动物心脏形态或功能产生任何异常改变,同时在骨骼肌达到治疗性表达。
- 对小鼠基因转移后心脏毒性及titin作用的进一步研究提示物种特异性titin剪接。
- 小鼠与NHP及人类相比缓冲calpain 3活性的能力降低。
- 研究强调calpain 3与titin结合位点之间存在复杂相互作用。
关键数值与推荐
- AAV9-desmin-hCAPN3载体剂量为3×10^13病毒基因组/kg。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Limb-girdle muscular dystrophy type 2A (LGMD2A or LGMDR1) is a neuromuscular disorder caused by mutations in the calpain 3 gene (CAPN3). Previous experiments using adeno-associated viral (AAV) vector-mediated calpain 3 gene transfer in mice indicated cardiac toxicity associated with the ectopic expression of the calpain 3 transgene. Here, we performed a preliminary dose study in a severe double-knockout mouse model deficient in calpain 3 and dysferlin. We evaluated safety and biodistribution of AAV9-desmin-hCAPN3 vector administration to nonhuman primates (NHPs) with a dose of 3 × 1013 viral genomes/kg. Vector administration did not lead to observable adverse effects or to detectable toxicity in NHP. Of note, the transgene expression did not produce any abnormal changes in cardiac morphology or function of injected animals while reaching therapeutic expression in skeletal muscle. Additional investigation on the underlying causes of cardiac toxicity observed after gene transfer in mice and the role of titin in this phenomenon suggest species-specific titin splicing. Mice have a reduced capacity for buffering calpain 3 activity compared to NHPs and humans. Our studies highlight a complex interplay between calpain 3 and titin binding sites and demonstrate an effective and safe profile for systemic calpain 3 vector delivery in NHP, providing critical support for the clinical potential of calpain 3 gene therapy in humans.
引用
- Lostal W, Roudaut C, Faivre M, et al. Titin splicing regulates cardiotoxicity associated with calpain 3 gene therapy for limb-girdle muscular dystrophy type 2A. Sci Transl Med. 2019. PMID: 31776291. doi:10.1126/scitranslmed.aat6072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。